Findings

What do systematic reviews say?

335 questions · 340 findings · 46 reviews · Pain, Palliative and Supportive Care

Sort:Best matchNewest Highest certainty Download CSV

No studies found 66 · 19.4%GRADE not reported 16 · 4.7%Very low 102 · 30%Low 68 · 20%Moderate 59 · 17.4%High 29 · 8.5%

Botulinum toxin type A vs placebo

Number of headache days per month: chronic migraine only · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1384 participants
High

Botulinum toxin type A vs placebo

Migraine frequency Number of attacks · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 2004 participants
Low

Botulinum toxin type A vs placebo

Headache intensity (mean score) · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 209 participants
Very low

Botulinum toxin type A vs placebo

Number experiencing adverse effects · adults with migraine

Botulinum toxin type A probably leads to higher total number of participants experiencing an adverse event compared with placebo (moderate certainty).

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
RR 1.28 [1.12, 1.47]
13 studies · 3325 participants
Moderate

Botulinum toxin type A vs other established prophylactic agent

Number of migraine days per month: chronic migraine only · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 43 participants
Very low

Botulinum toxin type A vs other established prophylactic agent

Headache (frequency) · adults with migraine

1 finding from 1 review

Botulinum toxins for the prevention of migraine in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Very low

Olanzapine vs placebo/no treatment

No nausea or vomiting over trial period · cancer patients

Olanzapine probably leads to higher no nausea or vomiting over trial period compared with placebo/no treatment (moderate certainty).

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
RR 1.98 [1.59, 2.47]
Studies not reported
Moderate

Olanzapine vs NK1 antagonist

Participant satisfaction · cancer patients

The review found no eligible studies for this question.

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Olanzapine vs NK1 antagonist

Quality of life · cancer patients

The review found no eligible studies for this question.

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Olanzapine vs NK1 antagonist

Other adverse events · cancer patients

The review found no eligible studies for this question.

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Olanzapine vs NK1 antagonist

Somnolence/fatigue · cancer patients

It is very uncertain whether olanzapine changes somnolence/fatigue compared with NK1 antagonist (very low certainty).

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
RR 1.33 [0.4, 4.49]
Studies not reported
Very low

Olanzapine vs placebo/no treatment

Serious adverse events · cancer patients

Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
RR 2.46 [0.48, 12.55]
Studies not reported
Low

Olanzapine vs placebo/no treatment

Quality of life · cancer patients

The review found no eligible studies for this question.

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Olanzapine vs placebo/no treatment

Other adverse events · cancer patients

Olanzapine showed no clear difference in other adverse events compared with placebo/no treatment (low certainty).

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
RR 1.71 [0.99, 2.96]
Studies not reported
Low

Olanzapine vs placebo/no treatment

Somnolence/fatigue · cancer patients

Olanzapine probably leads to higher somnolence/fatigue compared with placebo/no treatment (moderate certainty).

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
RR 2.33 [1.3, 4.18]
Studies not reported
Moderate

Olanzapine vs NK1 antagonist

No nausea or vomiting over trial period · cancer patients

The review found no eligible studies for this question.

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Olanzapine vs NK1 antagonist

Serious adverse events · cancer patients

It is very uncertain whether olanzapine changes serious adverse events compared with NK1 antagonist (very low certainty).

1 finding from 1 review

Olanzapine for the prevention and treatment of cancer‐related nausea and vomiting in adults 2018 · Cochrane Headline outcomes only
RR 0.33 [0.02, 7.32]
Studies not reported
Very low

Amitriptyline vs gabapentin

Participant‐reported pain relief of 30% or greater · children and adolescents with chronic non‐cancer pain

The review found no eligible studies for this question.

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amitriptyline vs placebo

Adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low

Amitriptyline vs placebo

Serious adverse events · children and adolescents with chronic non‐cancer pain

1 finding from 1 review

Antidepressants for chronic non‐cancer pain in children and adolescents 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 123 participants
Very low